Lupin
Lupin is a global pharmaceutical company operating in over 100 countries, employing over 20,000 people, and known for its leadership in the Anti-Tuberculosis segment and diverse product offerings in key therapeutic areas.
Company Overview
Lupin is a global pharmaceutical company that operates in over 100 countries and employs more than 20,000 people. The company manages 15 state-of-the-art manufacturing facilities located in India, the US, Brazil, and Mexico. Lupin is a global leader in the Anti-Tuberculosis segment and offers a diverse array of products, including branded and generic formulations, biotech products, Active Pharmaceutical Ingredients (API), and specialty drugs.
Product Offerings
Lupin offers a wide range of products in key therapeutic areas such as diabetes, cardiology, respiratory, and ophthalmology. The company provides both branded and generic formulations, biotech products, APIs, and specialty drugs. Lupin's over-the-counter (OTC) products are marketed through divisions like LupinLife Consumer Care in India and Pharmacy Action in Australia. In response to the COVID-19 pandemic, Lupin launched Covihalt (Favipiravir) in India for the treatment of COVID-19 and Albuterol in the US, a key rescue inhalation product.
Manufacturing Facilities
Lupin operates 15 state-of-the-art manufacturing facilities that are strategically located across India, the US, Brazil, and Mexico. These facilities are integral to the company's ability to produce a wide array of pharmaceutical products, including APIs, generic formulations, and specialty drugs. The company's extensive manufacturing capabilities ensure the production of high-quality medications that meet global standards.
Corporate Social Responsibility
Lupin is deeply engaged in corporate social responsibility (CSR) activities, impacting 2.5 million lives across nine states. The company's CSR initiatives include healthcare, education, and community development projects aimed at improving the quality of life for underprivileged communities. Lupin also participated in global COVID-19 relief efforts by providing both monetary and material support, including contributions to the PM CARES Fund and other initiatives.
COVID-19 Response
In response to the COVID-19 pandemic, Lupin launched several initiatives to support global efforts against the virus. The company introduced Covihalt (Favipiravir) in India for the treatment of COVID-19 and Albuterol in the US, a key rescue inhalation product. Lupin also contributed to the PM CARES Fund and other relief efforts, providing monetary and material support to help combat the pandemic.